Mylan
Mylan, now operating as Viatris Inc. following its 2020 merger with Pfizer's Upjohn division, is a publicly traded global pharmaceutical company (NASDAQ: VTRS) that manufactures and distributes generic and off-patent branded medicines to patients, pharmacies, and healthcare providers across more than 165 countries and territories.
- Company typePublic
- Founded2020
- Headquarters—
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Mylan does
Mylan N.V., originally founded in 1961 as a generic pharmaceutical company, merged with Upjohn Inc. (a former division of Pfizer Inc.) in November 2020 to form Viatris Inc., a global healthcare company publicly traded on NASDAQ under the ticker VTRS. The combined entity operates as an integrated pharmaceutical platform focused on the manufacture, development, and distribution of generic and off-patent branded medicines, with operations spanning more than 165 countries and territories served through approximately 50 manufacturing facilities with an aggregate annual production capacity exceeding 80 billion units.
The company's core product offering is generic pharmaceuticals and medications distributed globally through two primary channels: traditional retail pharmacy distribution for prescription and over-the-counter medications serving end patients, and direct supply relationships with hospitals, clinics, and healthcare systems. Its technology stack is centered on pharmaceutical manufacturing processes and generic drug development rather than software or AI capabilities. The business operates on a sales-led go-to-market motion, monetizing through one-time prescription-based pharmaceutical sales with pricing not publicly disclosed.
Viatris serves two primary customer segments: end-use patients and healthcare consumers requiring access to affordable medications across geographies, and healthcare providers and pharmacies requiring reliable supply of quality medicines. The company's stated value proposition centers on ensuring access to high-quality, affordable medicines regardless of geography, underpinned by sustainable operations and innovative healthcare solutions, including global health initiatives such as HIV/AIDS treatment access programs supported through a network of 60+ partner organizations worldwide.
Mylan firmographics
Firmographics- Name
- Mylan
- Legal name
- Viatris Inc.
- Website
- https://mylan.pt
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mylan, now operating as Viatris Inc. following its 2020 merger with Pfizer's Upjohn division, is a publicly traded global pharmaceutical company (NASDAQ: VTRS) that manufactures and distributes generic and off-patent branded medicines to patients, pharmacies, and healthcare providers across more than 165 countries and territories.
- Ownership category
- akta.pro rank
Mylan industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Specialty Pharmaceutical Distributors (HLAIAJAB), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)
Keywords
Mylan business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceutical Sales: Mylan generates revenue through the manufacture and sale of generic pharmaceuticals and medications. Following its merger with Upjohn to form Viatris, the combined entity operates with a focus on providing access to high-quality medicines globally.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Mylan product offering
Product offeringCore offering
Mylan, which merged with Upjohn (a Pfizer division) in November 2020 to form Viatris Inc., manufactures and sells generic pharmaceuticals and medications. The company operates approximately 50 manufacturing facilities globally, producing 80+ billion units annually, and distributes medicines across 165+ countries and territories through pharmacies and healthcare provider networks.
Product overview
Viatris is a single unified global healthcare company formed through the merger of Mylan and Upjohn. The company operates as one integrated platform offering pharmaceutical products and healthcare services, with manufacturing capabilities spanning approximately 50 factories worldwide and distribution across more than 165 countries and territories.
Differentiator
Problem solved
Functional benefit
Products and services
- Viatris (global healthcare company formed from Mylan and Upjohn merger)
Quantifiable outcome
- Access to medications across 165+ countries and territories
Companies that use Mylan
Customer profileSegments2 records
Ideal customer profiles2 records
Mylan technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Mylan partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Partner Organizations (60+ globally)coreViatris leverages partnerships with 60+ organizations worldwide to connect people to pharmaceutical products and services. The partnership ecosystem includes collaborations for access to medicines, healthcare solutions, and global health initiatives including HIV/AIDS treatment programs.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Mylan competitors and assessment
Company assessmentDirect peers
- Sun Pharmaceutical Industries: India-headquartered global generic manufacturer with a broad specialty generics portfolio and large US presence. Direct competitor to Viatris in generic formulations and specialty generics.
- Apotex: Canada-headquartered global generic drug manufacturer. Comparable to Viatris in generic finished dosage forms and global distribution, particularly in North America and select international markets.
- Cipla: India-based global pharmaceutical company with strong generics and respiratory franchises. Direct competitor to Viatris, particularly in emerging markets and HIV/AIDS therapies.
- Sandoz (Novartis): Global generics and biosimilars business spun out of Novartis. Competes head-to-head with Viatris in generic small molecules and biosimilars across the same 165+ country footprint.
- Lupin Pharmaceuticals: India-headquartered global generic manufacturer with significant US generics business. Competes with Viatris in oral solids, injectables, and specialty respiratory generics.
- Aurobindo Pharma: Large Indian generic manufacturer with a wide product portfolio and significant US and EU generics business. Directly competes with Viatris on price and scale across multiple molecules.
- Teva Pharmaceutical Industries: Largest global generic drug manufacturer with a broad specialty and generics portfolio. Direct peer to Viatris across both generic and off-patent branded segments, with comparable global distribution and manufacturing scale.
- Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical manufacturer with a broad generics portfolio, injectables, and biosimilars pipeline. Directly competes with Viatris across US generic channels.
- Hikma Pharmaceuticals: Jordan-headquartered global generic and specialty pharmaceutical company with strong US injectables and generics franchises. Comparable to Viatris in generic and injectable products across multiple geographies.
- Dr. Reddy's Laboratories: India-based global generics and biosimilars company with strong US presence. Comparable to Viatris in generic small molecules, complex generics, and biosimilars.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Mylan social profiles
Digital presenceMylan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mylan leadership team
Management profileNumber of profiles
Profiles1 record
Mylan subsidiaries and ownership
Company hierarchySubsidiaries1 record
Mylan funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mylan M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mylan
What does Mylan do?
Mylan, which merged with Upjohn (a Pfizer division) in November 2020 to form Viatris Inc., manufactures and sells generic pharmaceuticals and medications. The company operates approximately 50 manufacturing facilities globally, producing 80+ billion units annually, and distributes medicines across 165+ countries and territories through pharmacies and healthcare provider networks.
Is Mylan a public or private company?
Mylan is a public company. It is classified as public and is currently operating.
When was Mylan founded?
Mylan was founded in 2020. It employs 11 to 50 people.
How does Mylan make money?
One revenue line is on record: generic Pharmaceutical Sales.
Who are Mylan's main competitors?
Direct peers on record are Sun Pharmaceutical Industries, Apotex, Cipla, Sandoz (Novartis), Lupin Pharmaceuticals, Aurobindo Pharma, Teva Pharmaceutical Industries, Amneal Pharmaceuticals, Hikma Pharmaceuticals and Dr. Reddy's Laboratories.
Does Mylan have an API?
No public API is recorded for Mylan.
What industry is Mylan in?
Mylan's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.